<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92353">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01832454</url>
  </required_header>
  <id_info>
    <org_study_id>00160</org_study_id>
    <nct_id>NCT01832454</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years</brief_title>
  <acronym>BMCP2</acronym>
  <official_title>Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chaitanya Hospital, Pune</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chaitanya Hospital, Pune</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Study is Single arm, Single Centre trail to check the safety and efficacy of bone
      marrow derived autologous mononuclear cells(100 millions per dose )trial to be conducted for
      36 months in 100 patients ( below 15 years of age) with cerebral palsy in India. Primary
      outcome measures are improvement in walking ability and kinetic gait pattern.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Study is Single arm, Single Centre trail to check the safety and efficacy of bone
      marrow derived autologous mononuclear cells(100 millions per dose )trial to be conducted for
      36 months in 100 patients ( below 15 years of age) with cerebral palsy in India. Primary
      outcome measures are improvement in walking ability and kinetic gait pattern
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Improvement in muscle rigidity using Ash worth scale and   overall motor control using oxford scale.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>- Improvement in muscle rigidity using Ash worth scale and   overall motor control using oxford scale at Time point - 6 Months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>-Improvement in IQ by using Benit Kamat scale.</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>-Improvement in IQ by using Benit Kamat scale. Improvement in social behaviour. Reduction in deformity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>Intra thecal inj of autologous MNC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intra thecal inj of autologous MNC</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intra thecal inj of autologous MNC</intervention_name>
    <description>Intra thecal inj of autologous MNC</description>
    <arm_group_label>Intra thecal inj of autologous MNC</arm_group_label>
    <other_name>Intra thecal inj of autologous MNC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject aged above 3 years and below 15 years with a diagnosis of Cerebral Palsy.

          -  Regional Nerve damage  as shown by Magnetic Resonance Imaging(MRI)

          -  Able to Comprehend and give written informed consent form for the study

          -  willing to come to the hospital for follow up visits as per the protocol requirements

        Exclusion Criteria:

          -  History of meningitis,meningoencephalits,epilepsy or life threatening allergic or
             immune -mediated reaction 2

          -  Hemodynamically unstable patients

          -  history of or concurrent autoimmune disease or acute episode if Guillain- barre
             syndrome

          -  peripheral Muscular dystropy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anant E Bagul, M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>chaitanya stem cell centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chaitnany Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411009</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sachin A Jamadar, D ORTHO</last_name>
      <phone>+918888788880</phone>
      <email>sac2751982@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Smita S Bhoyar, BAMSPGCR</last_name>
      <phone>9372620569</phone>
      <email>drsmitabhoyar@rediffmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dr, Anant E Bagul, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 12, 2013</lastchanged_date>
  <firstreceived_date>February 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chaitanya Hospital, Pune</investigator_affiliation>
    <investigator_full_name>Dr. Sachin Jamadar</investigator_full_name>
    <investigator_title>CO-Investigator</investigator_title>
  </responsible_party>
  <keyword>cerebral palsy  stem cells [MNCS]</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Paralysis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
